Research ExplorerPublicationsEffects of tumour stage, comorbidity and therapy on survival...

Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis

Standard

Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis. / Rudolph, Elisabeth; Dyckhoff, Gerhard; Becher, Heiko; Dietz, Andreas; Ramroth, Heribert.

In: EUR ARCH OTO-RHINO-L, Vol. 268, No. 2, 01.02.2011, p. 165-79.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rudolph, E, Dyckhoff, G, Becher, H, Dietz, A & Ramroth, H 2011, 'Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis', EUR ARCH OTO-RHINO-L, vol. 268, no. 2, pp. 165-79. https://doi.org/10.1007/s00405-010-1395-8

APA

Rudolph, E., Dyckhoff, G., Becher, H., Dietz, A., & Ramroth, H. (2011). Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis. EUR ARCH OTO-RHINO-L, 268(2), 165-79. https://doi.org/10.1007/s00405-010-1395-8

Vancouver

Rudolph E, Dyckhoff G, Becher H, Dietz A, Ramroth H. Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis. EUR ARCH OTO-RHINO-L. 2011 Feb 1;268(2):165-79. https://doi.org/10.1007/s00405-010-1395-8

Bibtex

@article{526307f1ef674adcbf6832361c2d50a5,
title = "Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis",
abstract = "Laryngeal cancer is the second most common cancer of the respiratory tract with a relative 5-year survival over all tumour sites in the USA (61.6%; SEER 2009), which is much better than other head and neck cancers. The aim of this paper is to review and summarise data on the survival of laryngeal cancer patients. Literature search was conducted to identify articles in PubMed up to June 2009. Thirty studies with different study aims including sufficient information on survival of laryngeal cancer patients were identified. The 5-year overall survival ranged from 0 to 100%, depending on the T- and N-category, therapeutic approach and tumour location. The involvement of other factors such as genetics, nutrition and lifestyle habits remains uncertain. Our meta-analysis on a subgroup of published studies yielded an overall 5-year relative survival rate of 64.2% (95% confidence interval 63.7-64.7%). Different study aims and patient selection criteria prohibit general conclusions. However, this review may provide an actual picture of the complexity of factors influencing the survival of laryngeal cancer patients.",
keywords = "Disease-Free Survival, Humans, Laryngeal Neoplasms, Quality of Life, Survival Rate",
author = "Elisabeth Rudolph and Gerhard Dyckhoff and Heiko Becher and Andreas Dietz and Heribert Ramroth",
year = "2011",
month = feb,
day = "1",
doi = "10.1007/s00405-010-1395-8",
language = "English",
volume = "268",
pages = "165--79",
journal = "EUR ARCH OTO-RHINO-L",
issn = "0937-4477",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis

AU - Rudolph, Elisabeth

AU - Dyckhoff, Gerhard

AU - Becher, Heiko

AU - Dietz, Andreas

AU - Ramroth, Heribert

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Laryngeal cancer is the second most common cancer of the respiratory tract with a relative 5-year survival over all tumour sites in the USA (61.6%; SEER 2009), which is much better than other head and neck cancers. The aim of this paper is to review and summarise data on the survival of laryngeal cancer patients. Literature search was conducted to identify articles in PubMed up to June 2009. Thirty studies with different study aims including sufficient information on survival of laryngeal cancer patients were identified. The 5-year overall survival ranged from 0 to 100%, depending on the T- and N-category, therapeutic approach and tumour location. The involvement of other factors such as genetics, nutrition and lifestyle habits remains uncertain. Our meta-analysis on a subgroup of published studies yielded an overall 5-year relative survival rate of 64.2% (95% confidence interval 63.7-64.7%). Different study aims and patient selection criteria prohibit general conclusions. However, this review may provide an actual picture of the complexity of factors influencing the survival of laryngeal cancer patients.

AB - Laryngeal cancer is the second most common cancer of the respiratory tract with a relative 5-year survival over all tumour sites in the USA (61.6%; SEER 2009), which is much better than other head and neck cancers. The aim of this paper is to review and summarise data on the survival of laryngeal cancer patients. Literature search was conducted to identify articles in PubMed up to June 2009. Thirty studies with different study aims including sufficient information on survival of laryngeal cancer patients were identified. The 5-year overall survival ranged from 0 to 100%, depending on the T- and N-category, therapeutic approach and tumour location. The involvement of other factors such as genetics, nutrition and lifestyle habits remains uncertain. Our meta-analysis on a subgroup of published studies yielded an overall 5-year relative survival rate of 64.2% (95% confidence interval 63.7-64.7%). Different study aims and patient selection criteria prohibit general conclusions. However, this review may provide an actual picture of the complexity of factors influencing the survival of laryngeal cancer patients.

KW - Disease-Free Survival

KW - Humans

KW - Laryngeal Neoplasms

KW - Quality of Life

KW - Survival Rate

U2 - 10.1007/s00405-010-1395-8

DO - 10.1007/s00405-010-1395-8

M3 - SCORING: Journal article

C2 - 20957488

VL - 268

SP - 165

EP - 179

JO - EUR ARCH OTO-RHINO-L

JF - EUR ARCH OTO-RHINO-L

SN - 0937-4477

IS - 2

ER -